Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
- 31 January 2003
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 78 (1), 34-39
- https://doi.org/10.4065/78.1.34
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Current Therapy for Multiple MyelomaMayo Clinic Proceedings, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Angiogenesis in multiple myelomaSeminars in Oncology, 2001
- Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosisSeminars in Oncology, 2001
- Advances in disease biology: Therapeutic implicationsSeminars in Hematology, 2001
- Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myelomaAnnals of Hematology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983